Form 8-K

8-K — Esperion Therapeutics, Inc.

Accession: 0001104659-26-071814

Filed: 2026-06-09

Period: 2026-06-02

CIK: 0001434868

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Documents

8-K — tm2617356d1_8k.htm (Primary)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2617356d1_8k.htm · Sequence: 1

false

0001434868

2026-06-02

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 2, 2026

Esperion

Therapeutics, Inc.

(Exact name of Registrant as Specified in Its

Charter)

Delaware

001-35986

26-1870780

(State

or Other Jurisdiction of

Incorporation)

(Commission

File Number)

(IRS

Employer

Identification No.)

3891

Ranchero Drive, Suite 150

Ann

Arbor, Michigan

48108

(Address of Principal Executive Offices)

(Zip Code)

(734) 887-3903

(Registrant’s Telephone Number, Including

Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K filing

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

x Soliciting material pursuant to

Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange

Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant

to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common stock, par value $0.001 per share

ESPR

The

Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ¨

If an emerging

growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with

any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01.

Other Events.

As previously disclosed, on May 1, 2026, Esperion Therapeutics, Inc.,

a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”)

with Essence Parent Inc., a Delaware corporation and an affiliate of ArchiMed SAS (“Parent”), and Essence MergerCo Inc., a

Delaware corporation and wholly owned subsidiary of Parent (“MergerCo”), pursuant to which, subject to the terms and conditions

thereof, MergerCo will merge with and into the Company, with the Company surviving the merger as a wholly-owned subsidiary of Parent (the

“Merger”).

The completion of the Merger is conditioned upon, among other things,

the approval of the Merger by the Bundeskartellamt under the German Act Against Restraints of Competition (Gesetz Gegen Wettbewerbsbeschränkungen).

On June 8, 2026, the Company received notice, effective as of June 2, 2026, that the Bundeskartellamt cleared the Merger. The completion

of the Merger remains subject to the satisfaction of other closing conditions, including the expiration or termination of the applicable

waiting periods (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended from time to time,

and the adoption of the Merger Agreement by the Company’s stockholders.

As previously disclosed, the special meeting of Company stockholders

to consider adoption of the Merger Agreement has been scheduled to be held virtually on July 8, 2026 at 8:00 a.m. Eastern Time.

Forward-Looking Statements

Any statements in this Current Report on Form 8-K regarding the Company’s

future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute

“forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are

subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements.

Such statements include, but are not limited to, statements regarding Parent’s proposed acquisition of the Company, the ability

of Parent and the Company to complete the transactions contemplated by the Merger Agreement, including the parties’ ability to satisfy

the conditions set forth in the Merger Agreement, statements about the expected timetable for completing the Merger, the potential effects

of the pending acquisition on the Company, and the potential to achieve the milestones related to the contingent payments under the CVR,

and other statements containing the words “anticipates,” “believes,” “continue,” “expects,”

“intends,” “estimates,” “plans,” “may,” “will,” “could,” “would,”

“project,” “potential” and similar expressions. You should not place undue reliance on forward-looking statements

because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some

cases, beyond the Company’s control. These forward-looking statements are based upon the Company’s current expectations and

involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially

from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Such risks and uncertainties

include, without limitation, (i) the occurrence of any event, change or other circumstance that could give rise to the termination of

the Merger Agreement; (ii) the satisfaction (or waiver) of closing conditions to the consummation of the proposed transaction, including

the receipt of required regulatory approvals and the requisite approval of the Company’s stockholders; (iii) the effects of disruption

on the Company from the proposed transaction and the impact of the announcement and pendency of the proposed transaction on the Company’s

business, results of operations and financial condition; (iv) the effects of the proposed transaction on the Company’s relationships

with customers, employees, other business partners or governmental or regulatory entities; (v) the risks related to non-achievement of

any net sales milestone and that holders of the CVRs will not receive any payments in respect of the CVRs; (vi) the response of competitors

to the proposed transaction; (vii) risks associated with the disruption of management’s attention from ongoing business operations

due to the proposed transaction; (viii) the ability of the parties to consummate the proposed transaction in a timely manner or at all;

(ix) significant costs associated with the proposed transaction; (x) potential litigation relating to the proposed transaction; (xi) restrictions

during the pendency of the proposed transaction that may impact the Company’s ability to pursue certain business opportunities;

(xii) risks related to the net sales, profitability, commercial development and launch plans, and growth of the Company’s commercial

products; (xiii) risks and uncertainties related to regulatory applications, review and approval processes, and the Company’s compliance

with applicable legal and regulatory requirements; (xiv) general industry conditions, competition, and the outcomes and anticipated benefits

of legal proceedings and settlements; and (xv) general economic factors. These and other risks are described in additional detail in the

Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s other filings with the SEC, available

on the SEC’s website at www.sec.gov. All forward-looking statements contained in this Current Report on Form 8-K speak only as of

the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether because of new

information, future events or otherwise.

Additional Information and Where to Find It

In connection with the proposed transaction between the Company and

Parent, the Company has filed with the Securities and Exchange Commission (the “SEC”) a proxy statement on Schedule 14A (the

“Proxy Statement”) relating to a special meeting of its stockholders. Additionally, the Company may file other relevant materials

with the SEC in connection with the proposed transaction. Investors and securityholders of the Company are urged to read the Proxy Statement

and any other relevant materials filed or that will be filed with the SEC, as well as any amendments or supplements to these materials

and documents incorporated by reference therein, carefully and in their entirety when they become available because they contain or will

contain important information about the proposed transaction and related matters. The Proxy Statement has been mailed or otherwise made

available to the Company’s securityholders. Investors and securityholders are able to obtain a copy of the Proxy Statement as well

as other filings containing information about the proposed transaction that are filed by the Company with the SEC, free of charge on EDGAR

at www.sec.gov, on the investor relations page of the Company’s website at esperion.com/investors-media or by contacting the Company’s

investor relations department at investorrelations@esperion.com.

Participants in the Solicitation

The Company and certain of its directors and executive officers may

be deemed to be participants in the solicitation of proxies from the stockholders of the Company in respect of the proposed transaction

and any other matters to be voted on at the special meeting. Information about the Company’s directors and executive officers, including

a description of their direct interests, by security holdings or otherwise, can be found in the Company’s definitive proxy statement

for its 2026 Annual Meeting of Stockholders, as filed with the SEC on April 16, 2026 (available here). The Company’s stockholders

may obtain additional information regarding the direct and indirect interests of participants in the solicitation of proxies in connection

with the proposed transaction, including the interests of the Company’s directors and executive officers in the proposed transaction,

which may be different than those of the Company’s stockholders generally, by reading the Proxy Statement and any other relevant

documents that are filed or will be filed with the SEC relating to the proposed transaction (when available). You may obtain free copies

of these documents using the sources indicated above.

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Esperion Therapeutics, Inc.

Date: June 9,

2026

By:

/s/ Sheldon L. Koenig

Sheldon L.

Koenig

President and Chief Executive Officer

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Cover

Jun. 02, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 02, 2026

Entity File Number

001-35986

Entity Registrant Name

Esperion

Therapeutics, Inc.

Entity Central Index Key

0001434868

Entity Tax Identification Number

26-1870780

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3891

Ranchero Drive

Entity Address, Address Line Two

Suite 150

Entity Address, City or Town

Ann

Arbor

Entity Address, State or Province

Entity Address, Postal Zip Code

48108

City Area Code

734

Local Phone Number

887-3903

Written Communications

false

Soliciting Material

true

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, par value $0.001 per share

Trading Symbol

ESPR

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration